SCHEMBL359759

SCHEMBL359759

CCC[C@@H](OC(=O)C(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 8/20 0.57
PPARG P37231 2/20 0.50
PPARA Q07869 2/20 0.50
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
LMNA P02545 1/20 0.48
CHRM1 P11229 4/20 0.47
CHRM3 P20309 4/20 0.47
CHRM2 P08172 3/20 0.47
CHRM4 P08173 3/20 0.47
CYP3A4 P08684 3/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359760 1.00 KLK7 (0.57) KLK7PPARGPPARACYP1A2CYP2D6
SCHEMBL360673 0.91 KLK7 (0.59) KLK7PPARGCYP1A2CYP2D6LMNA
SCHEMBL360674 0.91 KLK7 (0.59) KLK7PPARGCYP1A2CYP2D6LMNA
SCHEMBL360653 0.87 KLK7 (0.68) KLK7CYP1A2CYP2D6LMNACHRM1
SCHEMBL360652 0.87 KLK7 (0.68) KLK7CYP1A2CYP2D6LMNACHRM1
SCHEMBL359777 0.83 PPARG (0.51) KLK7PPARGPPARACHRM1CHRM3
SCHEMBL359778 0.83 PPARG (0.51) KLK7PPARGPPARACHRM1CHRM3
SCHEMBL2859451 0.81 KLK7 (0.50) KLK7CYP1A2CYP2D6LMNACHRM1
SCHEMBL361291 0.81 KLK7 (0.54) KLK7CYP1A2CYP2D6LMNACHRM1
SCHEMBL2865464 0.81 CHRM1 (0.50) KLK7CYP1A2CYP2D6LMNACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2407447-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2018-04-18 EP disclosed
US-8552215-B2 Method for producing optically active 2-hydroxy ester and novel intermediate compound TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2013-10-08 US disclosed
EP-2407447-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND Tokyo University Of Science Educational Foundation Administrative Organization (JP) 2012-01-18 EP disclosed
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319650-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND CA7, HAO2, HACL2 KLK7 3948/4885PPARG 1463/4885PPARA 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.